5913 Results

People

  1. Ladanyi
    Ladanyi
  2. Solit
    Solit
  3. Levine
    Levine
  4. Berger
    Berger
  5. Schultz
    Schultz
  6. Arcila
    Arcila
  7. Hakimi
    Hakimi
  8. Chandarlapaty
    Chandarlapaty
  9. Zehir
    Zehir
  10. Mellinghoff
    Mellinghoff

Groups

  1. Human Oncology and Pathogenesis Program (5913)
  2. GSK Faculty (5696)
  3. Department of Medicine (4258)
  4. Department of Pathology and Laboratory Medicine (3036)
  5. Tow Center for Developmental Oncology (TCDO) (2612)
  6. Solid Tumor Oncology Division (2599)
  7. Sloan Kettering Institute Postdocs (1984)
  8. Hematologic Malignancies, Division of (1879)
  9. Center for Hematologic Malignancies (1845)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (1735)
  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (2984)
  2. Meeting Abstract (2526)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (41)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (15)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. Human Oncology and Pathogenesis Program (5913)
  2. GSK Faculty (5696)
  3. Department of Medicine (4258)
  4. Department of Pathology and Laboratory Medicine (3036)
  5. Tow Center for Developmental Oncology (TCDO) (2612)
  6. Solid Tumor Oncology Division (2599)

More Groups

People
  1. Marc Ladanyi (1326)
  2. David Solit (779)
  3. Ross Levine (774)
  4. Michael Berger (765)
  5. Nikolaus Schultz (486)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (119)
  2. 2024 (359)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (636)
  2. Blood (495)
  3. Cancer Research (412)
  4. Modern Pathology (299)
  5. Clinical Cancer Research (268)
  6. Laboratory Investigation (262)

More Publications

Publishers
  1. American Association for Cancer Research (871)
  2. Nature Publishing Group (757)
  3. American Society of Clinical Oncology (702)
  4. American Society of Hematology (541)
  5. Elsevier Inc. (420)
  6. Nature Research (312)

More Publishers

Results (5913)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed IDH2-mutant AML patients: 3-year follow-up
    Meeting Abstract

    Stein, E.; Cai, S. F.; Huang, Y.; Dunbar, A.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Schiller, G. J.; Olin, R. L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Attenuation of graft-versus-host-disease via genetic or pharmacologic inhibition of the RNA splicing factor RBM39
    Meeting Abstract

    Bourcier, J.; Hogg, S. J.; Erickson, C.; Singer, M. E.; Tittley, S.; Ito, T.; Egorova, A.; Kuttiyara, J.; Hanash, A. M.; Abdel-Wahab, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Microbial bile acid metabolism shapes effector T cell responses during inflammation in mouse and human
    Meeting Abstract

    Lindner, S.; Miltiadous, O.; Ramos, R. J.; Dai, A.; Kousa, A.; Armijo, G. K.; Ghale, R.; Nguyen, C. L.; Paredes Sanchez, J.; Fei, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Donor-derived amphiregulin drives CD4(+) T cell expansion and promotes tissue pathology after experimental allogeneic BMT
    Meeting Abstract

    Ito, T.; Takashima, S.; Calafiore, M.; Fu, Y. Y.; Egorova, A.; Kuttiyara, J.; Chang, W.; Vinci, P.; Arnhold, V.; Zaiss, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • RAF-Independent MEK mutations drive histiocytic neoplasms in vivo and are sensitive to single-agent ERK inhibition in patients
    Meeting Abstract

    Durham, B. H.; Singer, M. E.; Benbarche, S.; Erickson, C.; Rahman, J.; Solit, D. B.; Witkowski, M.; Rosen, N.; Abdel-Wahab, O.; Diamond, E. L.
    Blood (2022)

    Fulltext@MSK | Save
  • Characteristics and prognostic effects of DNMT3A co-mutations
    Meeting Abstract

    Torabi, A.; Alonzo, T. A.; Othus, M.; Gerbing, R. B.; Wang, Y. C.; Ries, R. E.; Radich, J. P.; Appelbaum, F. R.; O'Dwyer, K.; Erba, H. P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • JAK2(V617F) reversible activation shows an essential requirement for JAK2(V617F) in myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Dunbar, A.; Bowman, R. L.; Park, Y.; Izzo, F.; Myers, R. M.; Karzai, A.; Kim, W. J.; Maestre, I. F.; Waarts, M. R.; Nazir, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
    Journal Article

    Chatila, W. K.; Kim, J. K.; Walch, H.; Marco, M. R.; Chen, C. T.; Wu, F.; Omer, D. M.; Khalil, D. N.; Ganesh, K.; Qu, X.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • PIK3CA hotspot mutation generates a shared neoantigen targetable by TCR gene therapy
    Editorial

    Klebanoff, C. A.; Chandran, S. S.
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Clinical and pathologic determinants of outcome for non-optic pathway gliomas in adults with neurofibromatosis type 1
    Meeting Abstract

    Piotrowski, A. F.; Campian, J. L.; Brown, R.; Diarte, J.; Rodriguez, F.; Bale, T. A.; Dahiya, S.; Prichett, L.; Mellinghoff, I. K.; Blakeley, J. O.; more...
    Neurology (2022)

    Fulltext@MSK | Save